There are two nice examples (Myeloma and Hemochromatosis) that touch on the long term implications for people who may be tested repeatedly over time.
Both describe how repeated testing takes place depiste being asymptomatic and, potentially, over decades. They highlight how risk is an on-going, ever-present thing to be managed.
Shivani also raises a question about the US healthcare system and whether privatisation might drive testing... any thoughts?
